143 related articles for article (PubMed ID: 23483216)
1. Integrative genomic analyses of recepteur d'origine nantais and its prognostic value in cancer.
Yu H; Yuan J; Xiao C; Qin Y
Int J Mol Med; 2013 May; 31(5):1248-54. PubMed ID: 23483216
[TBL] [Abstract][Full Text] [Related]
2. Integrative genomic analyses of the histamine H1 receptor and its role in cancer prediction.
Wang M; Wei X; Shi L; Chen B; Zhao G; Yang H
Int J Mol Med; 2014 Apr; 33(4):1019-26. PubMed ID: 24535227
[TBL] [Abstract][Full Text] [Related]
3. Integrative genomic analyses of secreted protein acidic and rich in cysteine and its role in cancer prediction.
Wang B; Chen K; Xu W; Chen D; Tang W; Xia TS
Mol Med Rep; 2014 Sep; 10(3):1461-8. PubMed ID: 24938427
[TBL] [Abstract][Full Text] [Related]
4. Novel splicing variants of recepteur d'origine nantais (RON) tyrosine kinase involving exons 15-19 in lung cancer.
Krishnaswamy S; Mohammed AK; Amer OE; Tripathi G; Alokail MS; Al-Daghri NM
Lung Cancer; 2016 Feb; 92():41-6. PubMed ID: 26775595
[TBL] [Abstract][Full Text] [Related]
5. Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder.
Cheng HL; Liu HS; Lin YJ; Chen HH; Hsu PY; Chang TY; Ho CL; Tzai TS; Chow NH
Br J Cancer; 2005 May; 92(10):1906-14. PubMed ID: 15870710
[TBL] [Abstract][Full Text] [Related]
6. Integrative genomic analyses of the RNA-binding protein, RNPC1, and its potential role in cancer prediction.
Ding Z; Yang HW; Xia TS; Wang B; Ding Q
Int J Mol Med; 2015 Aug; 36(2):473-84. PubMed ID: 26046131
[TBL] [Abstract][Full Text] [Related]
7. Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumorigenic activities, and potential drug targets.
Lu Y; Yao HP; Wang MH
Cancer Lett; 2007 Nov; 257(2):157-64. PubMed ID: 17889431
[TBL] [Abstract][Full Text] [Related]
8. Crystal structure of the Sema-PSI extracellular domain of human RON receptor tyrosine kinase.
Chao KL; Tsai IW; Chen C; Herzberg O
PLoS One; 2012; 7(7):e41912. PubMed ID: 22848655
[TBL] [Abstract][Full Text] [Related]
9. Splice variants of the extracellular region of RON receptor tyrosine kinase in lung cancer cell lines identified by PCR and sequencing.
Krishnaswamy S; Mohammed AK; Tripathi G; Alokail MS; Al-Daghri NM
BMC Cancer; 2017 Nov; 17(1):738. PubMed ID: 29121914
[TBL] [Abstract][Full Text] [Related]
10. Structural basis for the binding specificity of human Recepteur d'Origine Nantais (RON) receptor tyrosine kinase to macrophage-stimulating protein.
Chao KL; Gorlatova NV; Eisenstein E; Herzberg O
J Biol Chem; 2014 Oct; 289(43):29948-60. PubMed ID: 25193665
[TBL] [Abstract][Full Text] [Related]
11. RON alternative splicing regulation in primary ovarian cancer.
Mayer S; Hirschfeld M; Jaeger M; Pies S; Iborra S; Erbes T; Stickeler E
Oncol Rep; 2015 Jul; 34(1):423-30. PubMed ID: 25997828
[TBL] [Abstract][Full Text] [Related]
12. Identification of the splice variants of Recepteur d'Origine nantais (RON) in lung cancer cell lines.
Krishnaswamy S; Bukhari I; Mohammed AK; Amer OE; Tripathi G; Alokail MS; Al-Daghri NM
Gene; 2018 Dec; 679():335-340. PubMed ID: 30223007
[TBL] [Abstract][Full Text] [Related]
13. Oncogenesis of RON receptor tyrosine kinase: a molecular target for malignant epithelial cancers.
Wang MH; Yao HP; Zhou YQ
Acta Pharmacol Sin; 2006 Jun; 27(6):641-50. PubMed ID: 16723080
[TBL] [Abstract][Full Text] [Related]
14. Identifying the role of Wilms tumor 1 associated protein in cancer prediction using integrative genomic analyses.
Wu LS; Qian JY; Wang M; Yang H
Mol Med Rep; 2016 Sep; 14(3):2823-31. PubMed ID: 27430156
[TBL] [Abstract][Full Text] [Related]
15. Recepteur d'origine nantais tyrosine kinase is a direct target of hypoxia-inducible factor-1alpha-mediated invasion of breast carcinoma cells.
Thangasamy A; Rogge J; Ammanamanchi S
J Biol Chem; 2009 May; 284(21):14001-10. PubMed ID: 19307182
[TBL] [Abstract][Full Text] [Related]
16. Recepteur d'origine nantais (RON), more than a kinase: Role in castrate-resistant prostate cancer.
Batth IS; Yun H; Kumar AP
Mol Carcinog; 2015 Oct; 54(10):937-46. PubMed ID: 26152593
[TBL] [Abstract][Full Text] [Related]
17. Effect of Recepteur d'Origine Nantais expression on chemosensitivity and tumor cell behavior in colorectal cancer.
Kim N; Cho SB; Park YL; Park SY; Myung E; Kim SH; Yu HM; Son YA; Myung DS; Lee WS; Joo YE
Oncol Rep; 2016 Jun; 35(6):3331-40. PubMed ID: 27035413
[TBL] [Abstract][Full Text] [Related]
18. Integrative genomic analyses on Ikaros and its expression related to solid cancer prognosis.
Yang L; Luo Y; Wei J
Oncol Rep; 2010 Aug; 24(2):571-7. PubMed ID: 20596648
[TBL] [Abstract][Full Text] [Related]
19. Multiple pulmonary adenomas in the lung of transgenic mice overexpressing the RON receptor tyrosine kinase. Recepteur d'origine nantais.
Chen YQ; Zhou YQ; Fu LH; Wang D; Wang MH
Carcinogenesis; 2002 Nov; 23(11):1811-9. PubMed ID: 12419829
[TBL] [Abstract][Full Text] [Related]
20. Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo.
Zhang Y; Kaplan-Lefko PJ; Rex K; Yang Y; Moriguchi J; Osgood T; Mattson B; Coxon A; Reese M; Kim TS; Lin J; Chen A; Burgess TL; Dussault I
Cancer Res; 2008 Aug; 68(16):6680-7. PubMed ID: 18701492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]